{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85"}]}],"title":"Anemia (Grade 2)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}],"title":"Anemia (Grade 3)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}],"title":"Hypertriglyceridemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Hyperglycemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Hyponatremia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Thrombocytopenia"}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"To determine the frequency and severity of toxicities associated with RAD001, letrozole, and metformin in this cohort of patients.","groups":[{"description":"Everolimus 10 mg PO daily + Letrozole 2.5 mg PO daily + Metformin 500 mg PO twice daily on a 4 week schedule","id":"OG000","title":"Rad-Let-Met"}],"paramType":"NUMBER","populationDescription":"59 patients who had at least one dose of treatment and had a follow up evaluation for side effects","reportingStatus":"POSTED","timeFrame":"93 months","title":"Percentage of Participants With Toxicities Associated With RAD001, Letrozole, and Metformin","type":"SECONDARY","unitOfMeasure":"percentage of participants"}